|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alberts SR, Cervantes A and van de Velde
CJ: Gastric cancer: Epidemiology, pathology and treatment. Ann
Oncol. 14 (Suppl 2):ii31–ii36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choi YY, Noh SH and Cheong JH: Evolution
of gastric cancer treatment: From the golden age of surgery to an
era of precision medicine. Yonsei Med J. 56:1177–1185. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang HM, Lee SW, Nomura E and Tanigawa N:
Laparoscopic versus open gastrectomy for gastric cancer patients
with COPD. J Surg Oncol. 100:456–458. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Foidart JM and Muschel RJ: Proteases and
Their Inhibitors in Cancer Metastasis. Kluwer Academic Publicers;
The Netherlands: pp. 225–252. 2002
|
|
7
|
Mesri M, Wall NR, Li J, Kim RW and Altieri
DC: Cancer gene therapy using survivin mutant adenovirus. J Clin
Invest. 108:981–990. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang L, Fang JY and Xu J: Gastric cancer
and gene copy number variation: Emerging cancer drivers for
targeted therapy. Oncogene. 35:1475–1482. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin Y, Wu Z, Guo W and Li J: Gene
mutations in gastric cancer: A review of recent next-generation
sequencing studies. Tumour Biol. 36:7385–7394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kajdaniuk D, Marek B, Borgielmarek H and
Koskudła B: Transforming growth factor β1 (TGFβ1) in physiology and
pathology. Endokrynol Pol. 64:384–396. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Massagué J: TGF-beta signal transduction.
Annu Rev Biochem. 67:753–791. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Assoian RK, Komoriya A, Meyers CA, Miller
DM and Sporn MB: Transforming growth factor-beta in human
platelets. Identification of a major storage site, purification,
and characterization. J Biol Chem. 258:7155–7160. 1983.PubMed/NCBI
|
|
13
|
Sam R, Wanna L, Gudehithlu KP, Garber SL,
Dunea G, Arruda JA and Singh AK: Glomerular epithelial cells
transform to myofibroblasts: Early but not late removal of
TGF-beta1 reverses transformation. Transl Res. 148:142–148. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ikushima H and Miyazono K: TGFbeta
signalling: A complex web in cancer progression. Nat Rev Cancer.
10:415–424. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Massagué J: TGFbeta in cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhuang J, Lu Q, Shen B, Huang X, Shen L,
Zheng X, Huang R, Yan J and Guo H: TGFβ1 secreted by
cancer-associated fibroblasts induces epithelial-mesenchymal
transition of bladder cancer cells through lncRNA-ZEB2NAT. Sci Rep.
5:119242015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neuzillet C, Tijeras-Raballand A, Cohen R,
Cros J, Faivre S, Raymond E and de Gramont A: Targeting the TGFβ
pathway for cancer therapy. Pharmacol Ther. 147:22–31. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Busch S, Acar A, Magnusson Y, Gregersson
P, Rydén L and Landberg G: TGF-beta receptor type-2 expression in
cancer-associated fibroblasts regulates breast cancer cell growth
and survival and is a prognostic marker in pre-menopausal breast
cancer. Oncogene. 34:27–38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ji Q, Liu X, Han Z, Zhou L, Sui H, Yan L,
Jiang H, Ren J, Cai J and Li Q: Resveratrol suppresses
epithelial-to-mesenchymal transition in colorectal cancer through
TGF-β1/Smads signaling pathway mediated Snail/E-cadherin
expression. BMC Cancer. 15:972015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma ZL, Hou PP, Li YL, Wang DT, Yuan TW,
Wei JL, Zhao BT, Lou JT, Zhao XT, Jin Y and Jin YX: MicroRNA-34a
inhibits the proliferation and promotes the apoptosis of non-small
cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol.
36:2481–2490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szász AM, Lánczky A, Nagy Á, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu X, Liu W, Tang D, Xiao H, Wu Z, Chen C,
Yao X, Liu F and Li G: Prognostic values of four Notch receptor
mRNA expression in gastric cancer. Sci Rep. 6:280442016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang S, Zhen W, Liu W, Lei R, Shan J, Li
L and Wang X: Distinct prognostic values of S100 mRNA expression in
breast cancer. Sci Rep. 7:397862017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu S, Xue W, Huang X, Yu X, Luo M, Huang
Y, Liu Y, Bi Z, Qiu X and Bai S: Distinct prognostic values of
ALDH1 isoenzymes in breast cancer. Tumor Biol. 36:2421–2426. 2015.
View Article : Google Scholar
|
|
25
|
Zhou X, Teng L and Wang M: Distinct
prognostic values of four-Notch-receptor mRNA expression in ovarian
cancer. Tumor Biol. 37:6979–6985. 2016. View Article : Google Scholar
|
|
26
|
Ivanova L, Zandberga E, Siliņa K, Kalniņa
Z, Ābols A, Endzeliņš E, Vendina I, Romanchikova N, Hegmane A,
Trapencieris P, et al: Prognostic relevance of carbonic anhydrase
IX expression is distinct in various subtypes of breast cancer and
its silencing suppresses self-renewal capacity of breast cancer
cells. Cancer Chemother Pharmacol. 75:235–246. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun Z, Wang ZN, Zhu Z, Xu YY, Xu Y, Huang
BJ, Zhu GL and Xu HM: Evaluation of the seventh edition of American
Joint Committee on Cancer TNM staging system for gastric cancer:
Results from a Chinese monoinstitutional study. Ann Surg Oncol.
19:1918–1927. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma J, Shen H, Kapesa L and Zeng S: Lauren
classification and individualized chemotherapy in gastric cancer.
Oncol Lett. 11:2959–2964. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Memon MA, Anway MD, Covert TR, Uzumcu M
and Skinner MK: Transforming growth factor beta (TGFbeta1, TGFbeta2
and TGFbeta3) null-mutant phenotypes in embryonic gonadal
development. Mol Cell Endocrinol. 294:70–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meng XM, Tang PM, Li J and Lan HY:
TGF-β/Smad signaling in renal fibrosis. Front Physiol. 6:822015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Okamura T, Morita K, Iwasaki Y, Inoue M,
Komai T, Fujio K and Yamamoto K: Role of TGF-β3 in the regulation
of immune responses. Clin Exp Rheumatol. 33 (Suppl 92):S63–S69.
2015.PubMed/NCBI
|
|
34
|
Potter RM, Huynh RT, Volper BD, Arthur KA,
D'Lugos AC, Sørensen MA, Magnusson SP, Dickinson JM, Hale TM and
Carroll CC: Impact of TGF-β inhibition during acute exercise on
Achilles tendon extracellular matrix. Am J Physiol Regul Integr
Comp Physiol. 312:R157–R164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Akhurst RJ and Derynck R: TGF-beta
signaling in cancer-a double-edged sword. Trends in Cell Biol.
11:S44–S51. 2001. View Article : Google Scholar
|
|
36
|
Costanza B, Umelo IA, Bellier J,
Castronovo V and Turtoi A: Stromal modulators of TGF-β in cancer. J
Clin Med. 6(pii): E72017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pang MF, Georgoudaki AM, Lambut L,
Johansson J, Tabor V, Hagikura K, Jin Y, Jansson M, Alexander JS,
Nelson CM, et al: TGF-β1-induced EMT promotes targeted migration of
breast cancer cells through the lymphatic system by the activation
of CCR7/CCL21-mediated chemotaxis. Oncogene. 35:748–760. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Docea AO, Mitruţ P, Grigore D, Pirici D,
Călina DC and Gofiţă E: Immunohistochemical expression of TGF beta
(TGF-β), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal
variant of gastric adenocarcinomas. Rom J Morphol Embryol. 53
(Suppl 3):683–692. 2012.PubMed/NCBI
|
|
39
|
Ma GF, Miao Q, Zeng XQ, Luo TC, Ma LL, Liu
YM, Lian JJ, Gao H and Chen SY: Transforming growth factor-β1 and
-β2 in gastric precancer and cancer and roles in tumor-cell
interactions with peripheral blood mononuclear cells in vitro. PLoS
One. 8:e542492013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
David CJ, Huang YH, Chen M, Su J, Zou Y,
Bardeesy N, Iacobuzio-Donahue CA and Massagué J: TGF-β tumor
suppression through a lethal EMT. Cell. 164:1015–1030. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang H, Liu L, Wang Y, Zhao G, Xie R, Liu
C, Xiao X, Wu K, Nie Y, Zhang H and Fan D: KLF8 involves in
TGF-beta-induced EMT and promotes invasion and migration in gastric
cancer cells. J Cancer Res Clin Oncol. 139:1033–1042. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiang J, Fu X, Ran W and Wang Z: Grhl2
reduces invasion and migration through inhibition of TGFβ-induced
EMT in gastric cancer. Oncogenesis. 6:e2842017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li C, Song L, Zhang Z, Bai XX, Cui MF and
Ma LJ: MicroRNA-21 promotes TGF-β1-induced epithelial-mesenchymal
transition in gastric cancer through up-regulating PTEN expression.
Oncotarget. 7:66989–67003. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zong W, Yu C, Wang P and Dong L:
Overexpression of SASH1 inhibits TGF-β1-induced EMT in gastric
cancer cells. Oncol Res. 24:17–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chang J, Park K, Bang YJ, Kim WS, Kim D
and Kim SJ: Expression of transforming growth factor beta type II
receptor reduces tumorigenicity in human gastric cancer cells.
Cancer Res. 57:2856–2859. 1997.PubMed/NCBI
|
|
47
|
Guo W, Dong Z, Guo Y, Chen Z, Yang Z and
Kuang G: Association of polymorphisms in transforming growth
factor-β receptors with susceptibility to gastric cardia
adenocarcinoma. Mol Biol Rep. 39:4301–4309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen J, Miao L, Jin G, Ren C, Ke Q, Qian
Y, Dong M, Li H, Zhang Q, Ding Y, et al: TGFBR1 tagging SNPs and
gastric cancer susceptibility: A two-stage case-control study in
Chinese population. Mol Carcinog. 53:109–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu L, Zeng Z, Chen B, Wu X, Yu J, Xue L,
Tian L, Wang Y, Chen M, Sung JJ and Hu P: Association between the
TGFB1 −509C/T and TGFBR2 −875A/G polymorphisms and gastric cancer:
A case-control study. Oncol Lett. 2:371–377. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pak KH, Dong HK, Kim H, Lee DH and Cheong
JH: Differences in TGF-β1 signaling and clinicopathologic
characteristics of histologic subtypes of gastric cancer. BMC
Cancer. 16:602016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Suzuki E, Kapoor V, Kaiser LR and Albelda
SM: Soluble type II TGF-β receptor augments or inhibits murine
malignant mesothelioma tumor growth depending on when it is
administered. Cancer Res. 64:53362004.
|
|
52
|
Chen ZL, Qin L, Peng XB, Hu Y and Liu B:
INHBA gene silencing inhibits gastric cancer cell migration and
invasion by impeding activation of the TGF-β signaling pathway. J
Cell Physiol. 234:18065–18074. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhou H, Wang K, Hu Z and Wen J: TGF-β1
alters microRNA profile in human gastric cancer cells. Chin J
Cancer Res. 25:102–111. 2013.PubMed/NCBI
|
|
54
|
Duan J, Zhang H, Qu Y, Deng T, Huang D,
Liu R, Zhang L, Bai M, Zhou L, Ying G and Ba Y: Onco-miR-130
promotes cell proliferation and migration by targeting TGFβR2 in
gastric cancer. Oncotarget. 7:44522–44533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jin G, Deng Y, Miao R, Hu Z, Zhou Y, Tan
Y, Wang J, Hua Z, Ding W, Wang L, et al: TGFB1 and TGFBR2
functional polymorphisms and risk of esophageal squamous cell
carcinoma: A case-control analysis in a Chinese population. J
Cancer Res Clin Oncol. 134:345–351. 2008. View Article : Google Scholar : PubMed/NCBI
|
